Laurus Labs Q4 Results & Technical Outlook

delivered an impressive Q4 performance, posting a net profit of ₹233.6 crore (vs ₹75.6 crore YoY and CNBC‑TV18 estimate of ₹185.4 crore) and EBITDA of ₹419 crore (74% YoY vs ₹398 crore est. — CNBC‑TV18), lifting its margin to 24.5% from 16.7% a year ago. CDMO revenues climbed 85% to ₹490 crore, generics rose 5%, and FDF grew 27%, offsetting an 8% drop in APIs. Management expects this momentum and new capacity ramps to drive FY26 revenue, while capital will remain focused on high‑value opportunities. Technically, share price is holding above its 9‑day EMA at ₹626.49, 70‑day EMA at ₹585.18, and 100‑day EMA at ₹584.56 after a peak near ₹660. The RSI at 61.70 suggests further upside before overbought territory. A sustained move above ₹660 could target ₹680–₹690, with support at the April pivot near ₹618 and the 100‑day EMA around ₹585. I have attached the daily chart of for your reference. Follow me for more such posts, Thank You! Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.